Samphire Neuroscience
San Francisco · Founded 2021
About Samphire Neuroscience
Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. It stimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women.
Company Facts
- Founded: 2021
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.3M
- Funding stage: Seed
- Last round: Seed (Jun 2025)
- Website: https://www.samphireneuro.com
- Phone: 302-377-9568
Industries & Categories
Artificial Intelligence (AI), Fitness, Health Care, Medical Device, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/samphire-neuroscience-93664 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.